| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3897369 | Seminars in Nephrology | 2006 | 7 Pages |
Abstract
The hemopoietic growth factor erythropoietin (EPO) has been recognized to be a multifunctional cytokine that plays a key role in ischemic preconditioning in the brain and heart. The EPO receptor is expressed widely in the kidney, and we review the important findings from the use of EPO in experimental models of acute renal failure that show that EPO reduces tubular cell death and hence the dysfunction induced by ischemia reperfusion injury, and we explore how these observations may be translated into the clinical arena.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Edward J. Sharples, Muhammad M. Yaqoob,